Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.
about
Current Cervical Carcinoma Screening GuidelinesPoint-Counterpoint: Cervical Cancer Screening Should Be Done by Primary Human Papillomavirus Testing with Genotyping and Reflex Cytology for Women over the Age of 25 Years.Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices.Psychosocial morbidity in women with abnormal cervical cytology managed by cytological surveillance or initial colposcopy: longitudinal analysis from the TOMBOLA randomised trialA study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results.Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test.Identifying a "range of reasonable options" for cervical cancer screening.Human Papillomavirus Laboratory Testing: the Changing ParadigmClinical Significance of an HPV DNA Chip Test with Emphasis on HPV-16 and/or HPV-18 Detection in Korean Gynecological Patients.Validation of Novaprep(®) HQ+ liquid-based cytology medium for high-risk human papillomavirus detection by hc2.Community-randomised controlled trial embedded in the Anishinaabek Cervical Cancer Screening Study: human papillomavirus self-sampling versus Papanicolaou cytology.Distribution of human papillomavirus genotypes in cervical lesionsCervical cancer screening in the era of HPV vaccination: A review of shifting paradigms in cytopathology.A Model Approach for Assessing the Benefits of HPV Testing against Cytology in Screening for Cervical Cancer Precursors in ThailandHPV Update: Vaccination, Screening, and Associated DiseaseClinician and Patient Acceptability of Self-Collected Human Papillomavirus Testing for Cervical Cancer Screening.Single Health System Adherence to 2012 Cervical Cancer Screening Guidelines at Extremes of Age and Posthysterectomy.Harms of cervical cancer screening in the United States and the Netherlands.Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.Human papillomavirus molecular biology.Proof-of-principle study of a novel cervical screening and triage strategy: Computer-analyzed cytology to decide which HPV-positive women are likely to have ≥CIN2.Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions.Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.Primary human papillomavirus testing.Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline.Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30-65 years.Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study.Self-collected cervicovaginal sampling for site-of-care primary HPV-based cervical cancer screening: a pilot study in a rural underserved Greek population.Dr. Bibbo's Presidential Address on Automation in Cytology: Were Her Predictions Right, Wrong, or Somewhere in the Middle?Test performance and acceptability of self- versus provider-collected swabs for high-risk HPV DNA testing in female-to-male trans masculine patients.Strategies to reach marginalized women for cervical cancer screening: A qualitative study of stakeholder perspectives.HPV16 viral load and physical state measurement as a potential immediate triage strategy for HR-HPV-infected women: a study in 644 women with single HPV16 infections.Evaluating a community-based cervical cancer screening strategy in Western Kenya: a descriptive study.The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications
P2860
Q26799522-6EE5A644-F5C7-454E-9303-0CFF740A939FQ30299986-09E514D2-2FF9-4255-B230-E98FDC9B0DE7Q30487807-6B4882AB-0388-411A-9848-ACFB5823A3EAQ33625941-AD3597EA-30B6-4DA0-8827-D27E7800D16FQ36016617-11756366-B49F-4180-8838-92D09929CA4DQ36187634-6F55CD35-F33F-4275-88F3-0EE7E088A498Q36483052-52A11441-616E-4B78-ABAD-B3F3007DAA20Q36675236-ACA7F3A7-BFB5-48A0-9D9B-E4C449D0EFE4Q37133271-1670E709-50C7-4F8D-BD47-2F6D803D5B4FQ37182286-EF073E9B-DC65-4868-917C-654410794DBBQ37355899-9A373520-B96F-48C4-9EC8-78F8BBAED12AQ37697709-51E1AB57-587D-4E81-8F00-50455AE9CF45Q38673879-6A83CAD8-434B-447A-ADC7-AD517D289ACDQ38727352-9958643A-8030-4301-8224-D7810055A1DEQ38835678-401C190C-EEC8-47C3-A2FA-1D65789714ACQ38884083-C04FD79C-536C-48FC-86BD-92DFC788504BQ38971928-FED29B01-2C3E-4B83-A1AC-1DAF5C415C92Q39172644-F1FDA827-2961-468C-9F98-8295AAC40ED4Q39204728-A03E5A3D-3EA1-4E98-969F-99779E217249Q39320611-8284A074-6B00-411B-BAA1-B4D73F7558AEQ39328580-9EE1281B-CE5A-4B54-A9CF-3CDABA0BAFC5Q40101106-A3F849F8-A2AF-4B60-A97C-A7954031CB40Q40142951-1AADB169-E2BF-435E-9837-239802F91E22Q40280339-F689064A-71E1-4A82-84F3-315296CDC371Q41466301-FCC08393-260F-48E4-AF66-AA4C5D44C584Q43924111-A1020097-D5A0-4DA6-A2AE-9F7DC41A9BD4Q47619776-A7C815BE-852F-454C-BBB2-1EF22C6203EFQ47790765-140A1E27-F77F-4B2E-B5CF-A95CDB44DCFAQ48251892-0E694000-CCA3-4436-BA67-C7CCC786C604Q48503787-1D1C6AF0-0862-4655-9CC1-90A5C3E0EFF2Q52655995-A010B37D-0351-432A-AC5F-57DC07BD9F86Q52673090-1EFC9B6E-215C-4CBD-AE9C-6F17528102D6Q54218651-E6400FF3-4BF2-451D-98A7-7D3E48D0E017Q55466473-6090B82F-66F9-4870-9475-2D5FDA780B7AQ58738110-8BC377E0-3729-4FC5-A20B-0172B40EBE31
P2860
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Use of primary high-risk human ...... ng: interim clinical guidance.
@en
type
label
Use of primary high-risk human ...... ng: interim clinical guidance.
@en
prefLabel
Use of primary high-risk human ...... ng: interim clinical guidance.
@en
P2093
P1476
Use of primary high-risk human ...... ng: interim clinical guidance.
@en
P2093
David Chelmow
Debbie Saslow
Diane D Davey
Edward J Mayeaux
Francisco A R Garcia
Herschel W Lawson
Kevin A Ault
L Stewart Massad
Mark H Einstein
Robert A Goulart
P304
P356
10.1097/AOG.0000000000000669
P407
P577
2015-02-01T00:00:00Z